Safe-T: Private Investment of NIS 22.5M supports positive momentum that is in line with company’s strategy. Target price raised to NIS 9.38

• jaimeuss_admin
• 17 בSeptember 2018
• Research
• 0 Comments

Continue Reading

RedHill Biopharma Ltd.: The acceleration of RHB-104 Phase III Study in Crohn’s disease increases company value and share price.

• jaimeuss_admin
• 17 בSeptember 2018
• Research
• 0 Comments

Continue Reading

DNA Biomedical Solutions Ltd.: The company and its holdings can become a major force in the osteoporosis care market, pending success in next year’s clinical trials.

• jaimeuss_admin
• 6 בSeptember 2018
• Research
• 0 Comments

Continue Reading

Vonetize Plc: Investment Opportunity in VOD for Emerging Countries and Israel; Agreement with Triple C is Expected to Significantly Increase Vonetize Revenues

• jaimeuss_admin
• 30 בAugust 2018
• Research
• 0 Comments

Continue Reading

Safe-T: Private Investment of NIS 22.5M supports positive momentum that is in line with company’s strategy. Target price raised to NIS 9.38

• jaimeuss_admin
• 30 בAugust 2018
• Research
• 0 Comments

Continue Reading